tuberculosis Syndicate content

Jun 03, 2019

SEONGNAM-SI, South Korea--(BUSINESS WIRE)--Qurient Co. Ltd. today announced positive results from the Phase 2a EBA (early bactericidal activity) clinical trial for telacebec (Q203), a first-in-class, orally-available antibiotic for the treatment of tuberculosis (TB). Telacebec is a selective inhibitor with high...